Marfan Syndrome Clinical Trials and Treatments

Marfan syndrome is an autosomal dominant connective tissue disorder caused by mutations in the FBN1 gene, encoding fibrillin-1, a key structural component of microfibrils essential for connective tissue integrity. Fibrillin dysfunction affects multiple body systems: skeletal (tall stature, long limbs, arachnodactyly, pectus deformities, scoliosis), ocular (lens dislocation, myopia, astigmatism), and cardiovascular (aortic root dilation, aortic dissection, mitral valve prolapse). The most serious manifestation is progressive aortic root dilation, which can lead to aortic dissection and rupture, a life-threatening emergency.

The most common symptoms of Marfan Syndrome include Tall stature with long limbs and arachnodactyly (long, slender fingers), Pectus deformities (sunken or pigeon chest), Lens dislocation (ectopia lentis), myopia, and astigmatism, Aortic root dilation and risk of aortic aneurysm and dissection, Mitral valve prolapse, among others. Marfan Syndrome affects approximately 1 in 5,000 to 1 in 10,000 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Marfan Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Protecting the aorta is the central goal in Marfan syndrome care, and researchers are working on improved medications that target TGF-beta signaling to slow aortic dilation more effectively than current options. Gene therapy approaches are also in early development.

As of October 21, 2026, no current FDA drug label names Marfan Syndrome as a condition the drug treats.

Marfan Syndrome is caused by variants in the FBN1 gene. At least 25% of cases are new (de novo) FBN1 variants.

It is autosomal dominant, so each child of an affected parent has a 1 in 2 chance of inheriting it. The condition affects approximately 1 in 5,000 to 1 in 10,000 people. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Marfan Syndrome looks at the FBN1 gene. At least 25% of cases are new (de novo) FBN1 variants.

It is autosomal dominant, so each child of an affected parent has a 1 in 2 chance of inheriting it.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Marfan Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Marfan Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.